-
摘要:
肿瘤治疗的个体化带来了临床实践变革。近年来，表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）对EGFR阳性突变的非小细胞肺癌显示出良好的抗肿瘤活性。第三代EGFR-TKIs相对于一代EGFR-TKI，显著提高了EGFR突变晚期非小细胞肺癌治疗的有效率、无进展生存期及总生存期，且对脑转移病灶有良好的疗效，对可手术的EGFR突变非小细胞肺癌术后辅助治疗也体现了无病生存获益，在联合放疗应用于局部晚期及晚期寡转移EGFR突变非小细胞肺癌中优势明显。
Abstract:The individualization of cancer treatment has brought about revolution in clinical practice. In recent years, EGFR-TKI has shown good anti-tumor activity in non-small cell lung cancer with EGFR positive mutation. Compared with the first-generation EGFR-TKI, the third-generation EGFR-TKI significantly increased the effective rate, progression-free survival and overall survival of advanced non-small cell lung cancer with EGFR mutation, especially the brain metastases. And the third-generation EGFR-TKI also showed the benefits of disease-free survival as the post-operative adjuvant therapy for operable EGFR-mutated non-small cell lung cancer. Moreover, the third-generation EGFR-TKI in combination with radiotherapy showed obvious advantages in the treatment of locally advanced and advanced oligometastatic EGFR-mutated non-small cell lung cancer.
-
Key words:
- Osimertinib /
- Almonertinib /
- Furmonertinib /
- EGFR mutation /
- Non-small cell lung cancer
-
Competing interests: The authors declare that they have no competing interests.作者贡献：许雯雯：论文撰写朱宇熹：论文审校
-
表 1 三代TKIs应用于晚期非小细胞肺癌的相关研究（疗效）
Table 1 Studies about third-generation TKIs on NSCLC (efficacy)
下载: 导出CSV
表 2 三代TKIs应用于晚期非小细胞肺癌的不良反应相关研究
Table 2 Studies about third-generation TKIs on NSCLC adverse events
下载: 导出CSV
-
[1] Li W, Qiu T, Guo L, et al. Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment[J]. Cancer Lett, 2018, 423: 9-15. doi: 10.1016/j.canlet.2018.03.005
[2] Wang S, Yan B, Zhang Y, et al. Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation[J]. Int J Cancer, 2019, 144(11): 2880-2886. doi: 10.1002/ijc.32015
[3] Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer[J]. N Engl J Med, 2017, 376(7): 629-640. doi: 10.1056/NEJMoa1612674
[4] Papadimitrakopoulou VA, Mok TS, Han JY, et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis[J]. Ann Oncol, 2020, 31(11): 1536-1544. doi: 10.1016/j.annonc.2020.08.2100
[5] Shi Y, Hu X, Zhang S, et al. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study[J]. Lancet Respir Med, 2021, 9(8): 829-839. doi: 10.1016/S2213-2600(20)30455-0
[6] Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2018, 378(2): 113-125. doi: 10.1056/NEJMoa1713137
[7] Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC[J]. N Engl J Med, 2020, 382(1): 41-50. doi: 10.1056/NEJMoa1913662
[8] Yi L, Fan J, Qian R, et al. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis[J]. Int J Cancer, 2019, 145(1): 284-294. doi: 10.1002/ijc.32097
[9] Miyashita Y, Ko R, Shimada N, et al. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation[J]. Thorac Cancer, 2021, 12(3): 329-338. doi: 10.1111/1759-7714.13742
[10] Zhou Y, Wang B, Qu J, et al. Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors[J]. Lung Cancer, 2020, 150: 178-185. doi: 10.1016/j.lungcan.2020.10.018
[11] Wu YL, Ahn MJ, Garassino MC, et al. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase Ⅲ Trial (AURA3)[J]. J Clin Oncol, 2018, 36(26): 2702-2709. doi: 10.1200/JCO.2018.77.9363
[12] Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer[J]. J Clin Oncol, 2018: JCO2018783118. http://www.ncbi.nlm.nih.gov/pubmed/30153097
[13] Yu HA, Schoenfeld AJ, Makhnin A, et al. Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial[J]. JAMA Oncol, 2020, 6(7): 1048-1054. doi: 10.1001/jamaoncol.2020.1260
[14] Wu YL, Herbst RS, Mann H, et al. ADAURA: Phase Ⅲ, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection[J]. Clin Lung Cancer, 2018, 19(4): e533-e536. doi: 10.1016/j.cllc.2018.04.004
[15] Wu YL, Tsuboi M, He J, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2020, 383(18): 1711-1723. doi: 10.1056/NEJMoa2027071
[16] Lu S, Casarini I, Kato T, et al. Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage Ⅲ Non-small-cell Lung Cancer: LAURA Trial in Progress[J]. Clin Lung Cancer, 2021, 22(4): 371-375. doi: 10.1016/j.cllc.2020.11.004
[17] Le X, Puri S, Negrao MV, et al. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC[J]. Clin Cancer Res, 2018, 24(24): 6195-6203. doi: 10.1158/1078-0432.CCR-18-1542
[18] Guo T, Ni J, Yang X, et al. Pattern of Recurrence Analysis in Metastatic EGFR-Mutant NSCLC Treated with Osimertinib: Implications for Consolidative Stereotactic Body Radiation Therapy[J]. Int J Radiat Oncol Biol Phys, 2020, 107(1): 62-71. doi: 10.1016/j.ijrobp.2019.12.042
[19] Jia WX, Guo HB, Wang J, et al. An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib[J]. Radiother Oncol, 2020, 152: 96-100. doi: 10.1016/j.radonc.2020.07.051
[20] Zheng MM, Li YS, Tu HY, et al. Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC[J]. J Thorac Oncol, 2021, 16(2): 250-258. doi: 10.1016/j.jtho.2020.10.008
[21] Yang JC, Ahn MJ, Kim DW, et al. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase Ⅱ Extension Component[J]. J Clin Oncol, 2017, 35(12): 1288-1296. doi: 10.1200/JCO.2016.70.3223
[22] Jiang T, Luo Y, Wang B. Almonertinib-induced interstitial lung disease: A case report[J]. Medicine(Baltimore), 2021, 100(3): e24393. http://www.ncbi.nlm.nih.gov/pubmed/33546082
[23] Mezquita L, Varga A, Planchard D. Safety of osimertinib in EGFR-mutated non-small cell lung cancer[J]. Expert Opin Drug Saf, 2018, 17(12): 1239-1248. doi: 10.1080/14740338.2018.1549222
[24] Yamamoto N, Mera T, Märten A, et al. Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib[J]. Adv Ther, 2020, 37(2): 759-769. doi: 10.1007/s12325-019-01187-y
[25] Hochmair MJ, Morabito A, Hao D, et al. Sequential afatinib and osimertinib in patients with mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study[J]. Future Oncol, 2019, 15(25): 2905-2914. doi: 10.2217/fon-2019-0346
[26] Marinis F, Wu YL, de Castro G Jr, et al. ASTRIS: a global real-world study of osimertinib in > 3000 patients with T790M positive non-small-cell lung cancer[J]. Future Oncol, 2019, 15(26): 3003-3014. doi: 10.2217/fon-2019-0324
[27] Mu Y, Xing P, Hao X, et al. Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung Cancer: A Retrospective Study[J]. Cancer Manag Res, 2019, 11: 9243-9251. doi: 10.2147/CMAR.S221434
[28] Lazzari C, Gregorc V, Karachaliou N, et al. Mechanisms of resistance to osimertinib[J]. J Thorac Dis, 2020, 12(5): 2851-2858. doi: 10.21037/jtd.2019.08.30
[29] Schmid S, Li JJN, Leighl NB. Mechanisms of osimertinib resistance and emerging treatment options[J]. Lung Cancer, 2020, 147: 123-129. http://www.sciencedirect.com/science/article/pii/S0169500220305365
[30] Zheng Q, Huang Y, Zhao H, et al. EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients[J]. Transl Lung Cancer Res, 2020, 9(3): 471-483. doi: 10.21037/tlcr.2020.03.35
[31] Yu D, Zhao W, Vallega KA, et al. Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling[J]. Lung Cancer, 2021, 12: 1-10. http://www.researchgate.net/publication/349058992_Managing_Acquired_Resistance_to_Third-Generation_EGFR_Tyrosine_Kinase_Inhibitors_Through_Co-Targeting_MEKERK_Signaling
-
期刊类型引用(5)
1. 曹呈尧，金家灿. 乳房全切术联合不同新辅助化疗治疗乳腺癌的疗效及影响因素分析. 浙江创伤外科. 2025(01): 142-146 . 
百度学术
2. 陈春春，唐经纬，孙岩峰，张浩，乔梦祥，郭伟. TCbHP新辅助化疗治疗HER-2阳性乳腺癌的临床疗效及其相关因素研究. 川北医学院学报. 2024(08): 1122-1126 . 百度学术
3. 王聪. 吡咯替尼联合曲妥珠单抗治疗人表皮生长因子受体2阳性乳腺癌患者的效果. 中国民康医学. 2024(20): 55-58 . 百度学术
4. 李丹，熊伟. 含注射用紫杉醇(白蛋白结合型)的新辅助TCbHP方案治疗老年乳腺癌的疗效. 临床合理用药. 2024(36): 105-107+111 . 百度学术
5. 陈世凤，陈怡. 定位针在乳腺癌新辅助化疗后保乳手术中的应用. 中外医药研究. 2024(33): 24-26 . 百度学术
其他类型引用(0)
计量
- 文章访问数: 2523
- HTML全文浏览量: 738
- PDF下载量: 905
- 被引次数: 5
